JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2005;58:1175-1179; doi:10.1136/jcp.2005.026955
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guan, M
Right arrow Articles by Chen, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guan, M
Right arrow Articles by Chen, Y

ORIGINAL ARTICLE

Aberrant expression of {Delta}Np73 in benign and malignant tumours of the prostate: correlation with Gleason score

M Guan, Y Chen

Centre of Laboratory Medicine, Hua Shan Hospital, Fudan University, Shanghai, 200040, PR China

Correspondence to:
Dr M Guan
Centre of Laboratory Medicine, Hua Shan Hospital, Fudan University, Shanghai, 200040, PR China; ming_guan88{at}yahoo.com Background: The p73 gene is a p53 homologue that induces apoptosis and inhibits cell proliferation. N-terminal truncated isoforms of p73 ({Delta}Np73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.

Aims: To detect {Delta}Np73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between {Delta}Np73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.

Methods: TAp73 was determined by real time polymerase chain reaction (PCR); {Delta}Np73 and {Delta}N’p73 were assessed using reverse transcription PCR. western blotting was used to analyse protein expression. p53 mutation was determined by immunohistochemistry.

Results: A significant increase of {Delta}Np73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples. None of the specimens expressed {Delta}N’p73. No significant relation was found between TAp73 expression and clinical parameters. The incidence of positive expression of {Delta}Np73 correlated with the Gleason score in prostate carcinomas. Cancer samples with wild-type p53 had significantly higher expression of {Delta}Np73 than p53 mutant cancers.

Conclusion: These data suggest a potential role for {Delta}Np73 in prostate cancer progression.


Abbreviations: {Delta}N, N truncated; BPH, benign prostate hyperplasia; Ct, cycle threshold; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PBS, phosphate buffered saline; PCa, prostate carcinoma; PCR, polymerase chain reaction; PSA, prostate specific antigen; RT, reverse transcriptase

Keywords: {Delta}Np73; p73; p53; prostate cancer




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
R. Malaguarnera, V. Vella, G. Pandini, M. Sanfilippo, V. Pezzino, R. Vigneri, and F. Frasca
TAp73{alpha} Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation
Mol. Cancer Res., January 1, 2008; 6(1): 64 - 77.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Tannapfel, K. John, N. Mise, A. Schmidt, S. Buhlmann, S. M. Ibrahim, and B. M. Putzer
Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73
Carcinogenesis, January 1, 2008; 29(1): 211 - 218.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Azare, K. Leslie, H. Al-Ahmadie, W. Gerald, P. H. Weinreb, S. M. Violette, and J. Bromberg
Constitutively Activated Stat3 Induces Tumorigenesis and Enhances Cell Motility of Prostate Epithelial Cells through Integrin {beta}6
Mol. Cell. Biol., June 15, 2007; 27(12): 4444 - 4453.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R Malaguarnera, V Vella, R Vigneri, and F Frasca
p53 family proteins in thyroid cancer
Endocr. Relat. Cancer, March 1, 2007; 14(1): 43 - 60.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. R. Watson, A. Blanch, D. C. C. Lin, M. Ohh, and M. S. Irwin
Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function
J. Biol. Chem., November 10, 2006; 281(45): 34096 - 34103.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.